Classification of Skeletal Muscle Relaxants

Skeletal muscle relaxants are classified into two types: spasmolytics and neuromuscular blockers. Spasmolytics, such as baclofen, act centrally to reduce involuntary muscle contractions from spinal diseases or injuries by activating inhibitory neurotransmitter receptors. Neuromuscular blockers act peripherally at the neuromuscular junction to induce paralysis during surgical anesthesia.

Baclofen acts on spinal nerves and activates receptors for GABA, an inhibitory neurotransmitter. This activation prevents excitatory neurotransmitters from firing motor neurons, thereby reducing involuntary and painful muscle contractions. Baclofen is commonly used to treat muscle stiffness arising from spinal diseases or injuries.

Non-depolarizing competitive neuromuscular blockers, such as rocuronium, prevent acetylcholine from binding to its receptors at the neuromuscular junction. By blocking the acetylcholine binding sites, these agents prevent muscle activation and induce relaxation. This competitive inhibition makes them useful for inducing paralysis during surgical procedures.

Depolarizing agents mimic acetylcholine by binding to its receptors and opening sodium channels in muscle cells. The resulting sodium ion influx extends membrane depolarization, causing repeated muscle contractions followed by temporary flaccid paralysis. This mechanism differs from non-depolarizing blockers, which prevent acetylcholine binding entirely.

Centrally acting muscle relaxants treat painful conditions characterized by muscle spasticity and rigidity, including multiple sclerosis, amyotrophic lateral sclerosis, and spinal injuries. These agents reduce muscle tone and spasms without altering consciousness, though they do have mild sedative effects. They work by reducing hyperreflexia and muscle stiffness.

Centrally acting muscle relaxants reduce muscle tone and spasms in the brain and spinal cord without interfering with neuromuscular transmission. Peripherally and centrally acting muscle relaxants differ in location and mechanism: peripheral agents work directly at the neuromuscular junction to induce paralysis, while central agents reduce tone systemically. The choice depends on whether the goal is pain relief or surgical paralysis.

Decamethonium and d-tubocurarine are depolarizing and non-depolarizing blockers, respectively, that are no longer utilized clinically. Modern alternatives such as rocuronium, vecuronium, and succinylcholine have replaced these older agents due to improved safety profiles, faster onset times, and better pharmacokinetic properties for surgical use.